CJC-1295 without DAC lacks the maleimidopropionyl-lysine Drug Affinity Complex modification present in the DAC variant, meaning it does not engage albumin-binding mechanisms that extend peptide stability in biological research systems. This results in a shorter stability window studied for its utility in experimental protocols modelling pulsatile growth hormone secretagogue signalling, which more closely approximates endogenous GHRH release patterns, in contrast to the sustained signalling profile associated with the DAC-modified variant.

CJC-1295 without DAC is structurally equivalent to Modified GRF(1-29) — a tetrasubstituted analogue of the native GHRH(1-29) sequence incorporating D-Ala2, Gln8, Ala15, and Leu27 substitutions for enhanced protease resistance. The naming distinction in research literature reflects historical convention: 'CJC-1295' strictly denotes the DAC-modified form, while 'CJC-1295 without DAC' and 'Modified GRF(1-29)' both describe the unmodified tetrasubstituted sequence without the albumin-binding moiety.

The single 2mg vial is suited to pilot studies, individual experimental runs, or protocols requiring a defined single-dose quantity, while the 10-vial KIT format supports larger research programs requiring multiple independent experimental replicates or extended timelines with consistent inter-vial compound quality. Researchers select format based on the total peptide quantity needed across all experimental arms and storage requirements for unused compound.